- /
- Supported exchanges
- / US
- / PBYI.NASDAQ
Puma Biotechnology Inc (PBYI NASDAQ) stock market data APIs
Puma Biotechnology Inc Financial Data Overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Puma Biotechnology Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Puma Biotechnology Inc data using free add-ons & libraries
Get Puma Biotechnology Inc Fundamental Data
Puma Biotechnology Inc Fundamental data includes:
- Net Revenue: 212 M
- EBITDA: 44 680 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 0.155
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Puma Biotechnology Inc News
New
December 2025's Promising Penny Stocks To Consider
As the U.S. markets show resilience with major indexes rising despite mixed economic signals, investors are increasingly looking beyond traditional stocks to explore other opportunities. Penny stocks,...
Stabilis Solutions And 2 Other Noteworthy Penny Stocks
As the U.S. markets close higher with a rebound in tech and crypto-related stocks, investors are keenly observing opportunities across various sectors. Penny stocks, despite being an older term, conti...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, December 02, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma’s Board ...
Promising Penny Stocks To Watch In December 2025
As the U.S. stock market experiences a slight uptick following a break in its recent winning streak, investors are closely monitoring the tech and crypto sectors for signs of rebound. Penny stocks, th...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.